$1.42
0.00% yesterday
Nasdaq, May 29, 10:05 pm CET
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Alector, Inc. Stock price

$1.42
+0.29 25.66% 1M
-1.17 45.17% 6M
-0.47 24.87% YTD
-3.58 71.60% 1Y
-7.78 84.57% 3Y
-31.28 95.66% 5Y
-15.21 91.46% 10Y
Nasdaq, Closing price Thu, May 29 2025
+0.00 0.00%
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Key metrics

Market capitalization $141.99m
Enterprise Value $-203.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.88
EV/Sales (TTM) EV/Sales -2.30
P/S ratio (TTM) P/S ratio 1.61
P/B ratio (TTM) P/B ratio 1.50
Revenue growth (TTM) Revenue growth -8.34%
Revenue (TTM) Revenue $88.34m
EBIT (operating result TTM) EBIT $-145.98m
Free Cash Flow (TTM) Free Cash Flow $-230.08m
Cash position $354.55m
EPS (TTM) EPS $-1.26
P/E forward negative
P/S forward 11.72
EV/Sales forward negative
Short interest 6.78%
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Alector, Inc. forecast:

5x Buy
63%
1x Hold
13%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Alector, Inc. forecast:

Buy
63%
Hold
13%
Sell
25%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
88 88
8% 8%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
2% 2%
65%
- Research and Development Expense 174 174
6% 6%
197%
-141 -141
1% 1%
-160%
- Depreciation and Amortization 4.95 4.95
14% 14%
6%
EBIT (Operating Income) EBIT -146 -146
0% 0%
-165%
Net Profit -123 -123
2% 2%
-140%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
GlobeNewsWire
21 days ago
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, wi...
Neutral
GlobeNewsWire
24 days ago
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada...
Neutral
GlobeNewsWire
about one month ago
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerati...
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 238
Founded 2013
Website alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today